BlogMay 22, 2024 Kimberly Chew Helps Physicians and Researchers Manage Legal Risks – Podcast Episode #49
PressMay 22, 2024 Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
Health & ScienceMay 21, 2024 Alaska Prepares for Potential Federal Legalization of Psychedelic Therapies
PressMay 21, 2024 Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services
PressMay 21, 2024 Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
PressMay 15, 2024 Filament Health Announces First Quarter 2024 Financial Results and Operational Highlights
PressMay 15, 2024 atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
PressMay 15, 2024 PharmaDrug’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
PressMay 14, 2024 Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
PressMay 14, 2024 Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
PressMay 13, 2024 PharmaDrug Provides Forward Plan to Move Its Patent Pending Process and Formulation of Pharmaceutical Grade Biosynthetic Cocaine Through Development into Commercialization
PressMay 13, 2024 AbbVie (ABBV) and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
